Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine[1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.[2]
The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope[3]) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).[4]
The US FDA granted it Breakthrough Therapy designation for glioblastoma in Feb 2015 meaning that it might be able to get approval sooner if it is effective.[5]
Clinical trials
Glioblastoma
The phase II ACT III study reported encouraging results in June 2015.[1]
The ReACT clinical trial for glioblastoma reported encouraging results in 2015.[2]
In March 2016 the phase III ACT IV trial [6] was terminated because it did not increase overall survival.[7]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
